Evidence map›Paper›PMID 37305926›Full record

ArticleDisease models & mechanisms2023

A novel porcine model of CLN3 Batten disease recapitulates clinical phenotypes.

Vicki J Swier, Katherine A White, Tyler B Johnson, Xiaojun Wang, Jimin Han, David A Pearce, Ruchira Singh, Arlene V Drack, Wanda Pfeifer, Christopher S Rogers and 2 more

Open access · goldAbstract read
In one paragraph

Article in Disease models & mechanisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. NF1Clinical and translational science · 2024
    Article
  9. Lysosomes in retinal health and disease.Trends in neurosciences · 2023
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Vicki J SwierPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD 57104, USA.ORCID 0000-0001-7509-9920
Katherine A WhitePediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD 57104, USA.ORCID 0000-0002-1663-1961
Tyler B JohnsonPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD 57104, USA.ORCID 0000-0002-6431-942X
Xiaojun WangPrecigen Exemplar, Coralville, IA 52241, USA.
Jimin HanDepartment of Ophthalmology , Center for Visual Science, University of Rochester Medical Center, Rochester, NY 14642, USA.ORCID 0000-0001-6911-7870
David A PearcePediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD 57104, USA.ORCID 0000-0002-0707-063X
Ruchira SinghDepartment of Ophthalmology , Center for Visual Science, University of Rochester Medical Center, Rochester, NY 14642, USA.ORCID 0000-0002-3821-1538
Arlene V DrackDepartment of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA 52242, USA.
Wanda PfeiferDepartment of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA 52242, USA.
Christopher S RogersPrecigen Exemplar, Coralville, IA 52241, USA.
Jon J BrudvigPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD 57104, USA.ORCID 0000-0002-3324-6125
Jill M WeimerPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD 57104, USA.ORCID 0000-0003-2504-4942
Sanford Research · USPrecigen (United States) · USUniversity of Iowa · USUniversity of Rochester Medical Center · USUniversity of South Dakota · US

Funding

The Impact of PD-1 Inhibition on Immune-Response to ChemoradiotherapyP20GM103548 · NIGMS · SANFORD RESEARCH/USD · PI MISKIMINS, W KEITH · 2012 to 2020
$20.8M
Transdisciplinary approaches to American Indian and rural population health researchP20GM121341 · NIGMS · SANFORD RESEARCH/USD · PI PUUMALA, SUSAN E · 2017 to 2022
$11.8M
Delineating the role of TIMP3 in macular degenerationR01EY028167 · NEI · UNIVERSITY OF ROCHESTER · PI SINGH, RUCHIRA · 2017 to 2025
$3.8M
RPE, aging and age-related macular degeneration: the role of oxidative stressR01EY027750 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI BONILHA, VERA L · 2017 to 2021
$2.0M
Determining the role of CLN3 in the eyeR01EY030183 · NEI · UNIVERSITY OF ROCHESTER · PI SINGH, RUCHIRA · 2019 to 2022
$2.0M
Using hiPSCs to develop physiologically-relevant outer retina tissue mimeticsR01EY033192 · NEI · UNIVERSITY OF ROCHESTER · PI BENOIT, DANIELLE S., SINGH, RUCHIRA · 2022 to 2024
$1.7M
hiPSC-derived tissue mimetics of the retina blood barrierR21EY030817 · NEI · UNIVERSITY OF ROCHESTER · PI BENOIT, DANIELLE S., SINGH, RUCHIRA · 2020 to 2021
$417k
Development of a Porcine Model of Juvenile Neuronal Ceroid LipofuscinosisR43NS081877 · NINDS · EXEMPLAR GENETICS, LLC · PI ROGERS, CHRISTOPHER · 2013 to 2013
$225k
NEI NIH HHS R01 EY027750NEI NIH HHS R01 EY028167NEI NIH HHS R01EY028167NEI NIH HHS R01 EY030183NEI NIH HHS R01 EY033192NEI NIH HHS R21 EY030817NIGMS NIH HHS P20 GM103548NIGMS NIH HHS P20GM103548NIGMS NIH HHS P20 GM121341NIH HHS P20GM103548NINDS NIH HHS NS081877NINDS NIH HHS R43 NS081877
6 · The paper itself

Abstract

Mouse models of CLN3 Batten disease, a rare lysosomal storage disorder with no cure, have improved our understanding of CLN3 biology and therapeutics through their ease of use and a consistent display of cellular pathology. However, the translatability of murine models is limited by disparities in anatomy, body size, life span and inconsistent subtle behavior deficits that can be difficult to detect in CLN3 mutant mouse models, thereby limiting their use in preclinical studies. Here, we present a longitudinal characterization of a novel miniswine model of CLN3 disease that recapitulates the most common human pathogenic variant, an exon 7-8 deletion (CLN3Δex7/8). Progressive pathology and neuron loss is observed in various regions of the CLN3Δex7/8 miniswine brain and retina. Additionally, mutant miniswine present with retinal degeneration and motor abnormalities, similar to deficits seen in humans diagnosed with the disease. Taken together, the CLN3Δex7/8 miniswine model shows consistent and progressive Batten disease pathology, and behavioral impairment mirroring clinical presentation, demonstrating its value in studying the role of CLN3 and safety/efficacy of novel disease-modifying therapeutics.

Indexed as

Lysosomal Storage DiseasesNeuronal Ceroid-LipofuscinosesAnimalsDisease Models, AnimalHumansMembrane GlycoproteinsMiceMolecular ChaperonesPhenotypeRetinaSwineCLN3 protein, humanCLN3 protein, mouseMembrane GlycoproteinsMolecular ChaperonesAnimal disease modelsJNCLNeuronal ceroid lipofuscinosisNeuropediatric disease

Identifiers

PMID37305926
PMCPMC10434985
OpenAlexW4380290811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.